Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clobeta is a topical corticosteroid medication developed and marketed by Saffron Pharma, available in both cream and ointment formulations. The active ingredient is clobetasol propionate, which is classified as a super-high potency (Group I) corticosteroid. It works by binding to cytoplasmic glucocorticoid receptors and subsequently moving into the cell nucleus, where it binds to glucocorticoid response elements (GREs) on the DNA. This action induces the synthesis of inhibitory proteins called lipocortins, which in turn inhibit phospholipase A2. By inhibiting this enzyme, Clobeta reduces the release of arachidonic acid, thereby decreasing the production of inflammatory mediators such as prostaglandins and leukotrienes. It is primarily used to treat severe inflammatory skin conditions, including psoriasis, eczema (including contact dermatitis), lichen planus, and skin manifestations of lupus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Clobeta.